BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poulsen NN, von Brunn A, Hornum M, Blomberg Jensen M. Cyclosporine and COVID-19: Risk or favorable? Am J Transplant 2020;20:2975-82. [PMID: 32777170 DOI: 10.1111/ajt.16250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van Geel N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies? Drugs R D 2021;21:341-50. [PMID: 34106430 DOI: 10.1007/s40268-021-00349-0] [Reference Citation Analysis]
2 Karmakar D, Lahiri B, Ranjan P, Chatterjee J, Lahiri P, Sengupta S. Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. Pathogens 2020;10:5. [PMID: 33374748 DOI: 10.3390/pathogens10010005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cigremis Y, Ozen H, Durhan M, Tunc S, Kose E. Effects of caffeic acid phenethyl ester use and inhibition of p42/44 MAP kinase signal pathway on caveolin 1 gene expression and antioxidant system in chronic renal failure model of rats. Drug and Chemical Toxicology. [DOI: 10.1080/01480545.2021.2016043] [Reference Citation Analysis]
4 Ferrari D, Locatelli M, Briguglio M, Lombardi G. Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity? Cell Biochem Funct 2021;39:35-47. [PMID: 33137851 DOI: 10.1002/cbf.3597] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
5 Nunn AVW, Guy GW, Brysch W, Botchway SW, Frasch W, Calabrese EJ, Bell JD. SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing. Immun Ageing 2020;17:33. [PMID: 33292333 DOI: 10.1186/s12979-020-00204-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
6 Nakayama M, Okada AA, Hayashi I, Ando Y, Watanabe T, Keino H. A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine. Ocul Immunol Inflamm 2022;:1-6. [PMID: 35167414 DOI: 10.1080/09273948.2022.2028293] [Reference Citation Analysis]
7 Ommati MM, Mobasheri A, Heidari R. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. J Biochem Mol Toxicol 2021;35:e22795. [PMID: 33973313 DOI: 10.1002/jbt.22795] [Reference Citation Analysis]
8 Farajzadeh S, Ahramiyanpour N. Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID-19 outbreak? Clin Case Rep 2021;9:e04249. [PMID: 34026201 DOI: 10.1002/ccr3.4249] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Torres T, Pereira M, Paiva Lopes MJ, Rebelo C, Andrade P, Henrique M, Oliveira H, Ferreira P, Marques Pinto G, Menezes Brandão F, Rozeira J, Filipe P, Tavares Bello R. Dermatologists' attitude towards psoriasis treatment during the COVID-19 pandemic. Drugs Context 2021;10:2021-4-4. [PMID: 34178094 DOI: 10.7573/dic.2021-4-4] [Reference Citation Analysis]
10 May MR, Rübben A, Lennertz A, Vanstreels L, Leijs M. Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection. JPM 2022;12:173. [DOI: 10.3390/jpm12020173] [Reference Citation Analysis]
11 Zetina-tun HJ, Careaga-reyna G. Infección por SARS-CoV-2 en pacientes trasplantados de corazón. Experiencia en México. Cirugía Cardiovascular 2022;29:21-4. [DOI: 10.1016/j.circv.2021.06.005] [Reference Citation Analysis]
12 Hasbal NB, Turgut D, Gok Oguz E, Ulu S, Gungor O. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients. Ann Transplant 2021;26:e929279. [PMID: 33707409 DOI: 10.12659/AOT.929279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Magnusson JM, Larsson H, Alsaleh A, Ekelund J, Karason K, Schult A, Friman V, Felldin M, Søfteland JM, Dellgren G, Oltean M. COVID-19 in lung transplant recipients: an overview of the Swedish national experience. Transpl Int 2021. [PMID: 34709680 DOI: 10.1111/tri.14148] [Reference Citation Analysis]
14 Devaux CA, Melenotte C, Piercecchi-Marti MD, Delteil C, Raoult D. Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19? Front Med (Lausanne) 2021;8:663708. [PMID: 34552938 DOI: 10.3389/fmed.2021.663708] [Reference Citation Analysis]
15 Mardani M, Hakamifard A. COVID-19 and immunocompromised conditions: Ongoing challenging issue. Eur J Inflamm 2021;19:205873922110161. [DOI: 10.1177/20587392211016114] [Reference Citation Analysis]